Kennedy Investment Group Purchases Shares of 19,672 Novo Nordisk A/S $NVO

Kennedy Investment Group purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,672 shares of the company’s stock, valued at approximately $1,001,000.

A number of other hedge funds have also recently made changes to their positions in NVO. Revolve Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after acquiring an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after acquiring an additional 1,587 shares during the period. Invesco Ltd. boosted its holdings in Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after acquiring an additional 87,467 shares during the period. Finally, Gamco Investors INC. ET AL bought a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $314,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Down 0.1%

NVO opened at $44.24 on Wednesday. The business has a 50 day simple moving average of $39.95 and a two-hundred day simple moving average of $46.54. The firm has a market capitalization of $197.52 billion, a price-to-earnings ratio of 10.38, a PEG ratio of 3.94 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion for the quarter. Analysts predict that Novo Nordisk A/S will post 3.47 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on NVO shares. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Wolfe Research started coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a report on Tuesday, March 3rd. Finally, Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk expanded its obesity pipeline with updates on the AMAZE 12 Phase 3 trial and a new cagrilintide study, reinforcing its push to maintain leadership beyond current blockbuster products. Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs
• Positive Sentiment: The company also announced a share repurchase program, which can support earnings per share and signals management confidence in Novo Nordisk’s cash generation. Novo Nordisk A-S share repurchase programme
• Neutral Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Novo Nordisk, adding a modestly constructive analyst note but not a major catalyst on its own.
• Neutral Sentiment: News coverage highlighted Novo Nordisk’s plan to push obesity treatments globally, especially outside the U.S., where the company sees a major growth opportunity. Novo Nordisk’s next obesity battlefront: Winning beyond America
• Negative Sentiment: Investors remain focused on intensifying competition from Eli Lilly and other GLP-1 rivals, with articles noting the race to launch obesity pills globally and the risk of new entrants pressuring Novo Nordisk’s market share. GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
• Negative Sentiment: Citi tracking showed Wegovy pill prescriptions slipped week over week, even though the drug still leads competitors, suggesting momentum is strong but not uninterrupted. Novo Nordisk’s Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.